Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akihisa Imagawa

Showing results (1-10 of 153) with videos related to

Pageof 16
Sort By:
Biology|November 24, 2022
Re-Enlightenment of Fulminant Type 1 Diabetes under the COVID-19 PandemicHiroyuki Sano, Akihisa Imagawa
Rinsho Byori. the Japanese Journal of Clinical Pathology|April 23, 2010
[Fulminant type 1 diabetes mellitus]Akihisa Imagawa, Toshiaki Hanafusa
Diabetology International|October 22, 2020
Fulminant type 1 diabetes: recent research progress and future prospectsAkihisa Imagawa, Megumi Tachibana
Journal of Diabetes Investigation|October 5, 2019
Pancreatic β-cells express major histocompatibility complex class II: Do diabetic β-cells have the capacity of antigen-presenting cells?Hiroyuki Sano, Akihisa Imagawa
Diabetes/Metabolism Research and Reviews|November 10, 2011
Fulminant type 1 diabetes--an important subtype in East AsiaAkihisa Imagawa, Toshiaki Hanafusa
Best Practice & Research. Clinical Endocrinology & Metabolism|April 22, 2022
Type 1 diabetes related to immune checkpoint inhibitorsMegumi Tachibana, Akihisa Imagawa
Journal of Diabetes Investigation|January 6, 2022
Research following genome-wide association study focuses on the multifaceted nature of Src kinase-associated phosphoprotein 2 in type 1 diabetesHiroyuki Sano, Akihisa Imagawa
The Review of Diabetic Studies : RDS|May 10, 2007
Pathogenesis of fulminant type 1 diabetesAkihisa Imagawa, Toshiaki Hanafusa
The Journal of Clinical Endocrinology and Metabolism|June 13, 2023
Fulminant Type 1 Diabetes-East and WestAkihisa Imagawa, Toshiaki Hanafusa
Nature Clinical Practice. Endocrinology & Metabolism|December 21, 2006
Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitionersToshiaki Hanafusa, Akihisa Imagawa
Pageof 16

Showing results (1-10 of 153) with videos related to

Sort By:
Pageof 16
Biology|November 24, 2022
Re-Enlightenment of Fulminant Type 1 Diabetes under the COVID-19 PandemicHiroyuki Sano, Akihisa Imagawa
Rinsho Byori. the Japanese Journal of Clinical Pathology|April 23, 2010
[Fulminant type 1 diabetes mellitus]Akihisa Imagawa, Toshiaki Hanafusa
Diabetology International|October 22, 2020
Fulminant type 1 diabetes: recent research progress and future prospectsAkihisa Imagawa, Megumi Tachibana
Journal of Diabetes Investigation|October 5, 2019
Pancreatic β-cells express major histocompatibility complex class II: Do diabetic β-cells have the capacity of antigen-presenting cells?Hiroyuki Sano, Akihisa Imagawa
Diabetes/Metabolism Research and Reviews|November 10, 2011
Fulminant type 1 diabetes--an important subtype in East AsiaAkihisa Imagawa, Toshiaki Hanafusa
Best Practice & Research. Clinical Endocrinology & Metabolism|April 22, 2022
Type 1 diabetes related to immune checkpoint inhibitorsMegumi Tachibana, Akihisa Imagawa
Journal of Diabetes Investigation|January 6, 2022
Research following genome-wide association study focuses on the multifaceted nature of Src kinase-associated phosphoprotein 2 in type 1 diabetesHiroyuki Sano, Akihisa Imagawa
The Review of Diabetic Studies : RDS|May 10, 2007
Pathogenesis of fulminant type 1 diabetesAkihisa Imagawa, Toshiaki Hanafusa
The Journal of Clinical Endocrinology and Metabolism|June 13, 2023
Fulminant Type 1 Diabetes-East and WestAkihisa Imagawa, Toshiaki Hanafusa
Nature Clinical Practice. Endocrinology & Metabolism|December 21, 2006
Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitionersToshiaki Hanafusa, Akihisa Imagawa
Pageof 16